Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)
Close on Nov 18, 2026Market cap $44.12MP/E –Yield –
Xilio Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Xilio Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $64.09M, up 327.3% year over year. For fiscal 2025 it was $43.77M, up 589.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.77M | +589.9% |
| FY2024 | Dec 31, 2024 | $6.34M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.69M | +131.2% |
| Q1 FY2026 | Mar 31, 2026 | $12.65M | +331.7% |
| Q4 FY2025 | Dec 31, 2025 | $13.69M | +693.9% |
| Q3 FY2025 | Sep 30, 2025 | $19.07M | +742.5% |
| Q2 FY2025 | Jun 30, 2025 | $8.08M | +243.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.93M | – |
| Q4 FY2024 | Dec 31, 2024 | $1.72M | – |
| Q3 FY2024 | Sep 30, 2024 | $2.26M | – |
| Q2 FY2024 | Jun 30, 2024 | $2.36M | – |
See a number that looks wrong?